BACKGROUND AND AIM: Neutrophil gelatinase associated lipocalin (NGAL) is a recently identified molecule, which is bacteriostatic, has tissue destructive effects and is pro-inflammatory with chemoattractant molecule binding properties. Our aim was to investigate the relationship between serum NGAL levels and the type and level of disease activity of IBD. METHODS: A total of 92 patients [43 with Crohn's disease (CD) and 49 with ulcerative colitis (UC)], and 30 age- and sex-matched healthy controls (HC) were included in this study. Serum NGAL levels were measured using ELISA. RESULTS: Serum NGAL levels were elevated in the IBD group [median 171, range (57-312) ng/mL] compared to the HC group [107 (45-234) ng/mL] (p<0.0001) and were elevated in UC patients [188 (74-312) ng/mL] compared to CD patients [168 (57-279) ng/mL] (p=0.006). When NGAL levels were further analysed based on localization of the CD and UC, the levels in ulcerative pancolitis [233 (144-312) ng/mL] were significantly higher (p=0.004) than the left-sided colitis [156 (103-309) ng/mL]. Similarly, NGAL levels were significantly higher in colonic CD [207 (125-249) ng/mL] than ileal CD [114 (78-210) ng/mL], and also in ileocolonic CD [198 (57-279) ng/mL] than ileal CD (p=0.033). When CD and UC groups were further categorized as active and inactive according to clinical and endoscopic activity indices, serum NGAL concentrations did not differ between inquiescent versus active stages. When a cut-off level of 129 ng/mL was used to distinguish IBD from HC, a sensitivity of 76.1% and a specificity of 60.9% was reached. CONCLUSIONS: The serum NGAL levels in the IBD group was significantly higher than the HC group. Serum NGAL levels were higher in more extensive colonic involvement.
BACKGROUND AND AIM: Neutrophil gelatinase associated lipocalin (NGAL) is a recently identified molecule, which is bacteriostatic, has tissue destructive effects and is pro-inflammatory with chemoattractant molecule binding properties. Our aim was to investigate the relationship between serum NGAL levels and the type and level of disease activity of IBD. METHODS: A total of 92 patients [43 with Crohn's disease (CD) and 49 with ulcerative colitis (UC)], and 30 age- and sex-matched healthy controls (HC) were included in this study. Serum NGAL levels were measured using ELISA. RESULTS: Serum NGAL levels were elevated in the IBD group [median 171, range (57-312) ng/mL] compared to the HC group [107 (45-234) ng/mL] (p<0.0001) and were elevated in UC patients [188 (74-312) ng/mL] compared to CDpatients [168 (57-279) ng/mL] (p=0.006). When NGAL levels were further analysed based on localization of the CD and UC, the levels in ulcerative pancolitis [233 (144-312) ng/mL] were significantly higher (p=0.004) than the left-sided colitis [156 (103-309) ng/mL]. Similarly, NGAL levels were significantly higher in colonic CD [207 (125-249) ng/mL] than ileal CD [114 (78-210) ng/mL], and also in ileocolonic CD [198 (57-279) ng/mL] than ileal CD (p=0.033). When CD and UC groups were further categorized as active and inactive according to clinical and endoscopic activity indices, serum NGAL concentrations did not differ between inquiescent versus active stages. When a cut-off level of 129 ng/mL was used to distinguish IBD from HC, a sensitivity of 76.1% and a specificity of 60.9% was reached. CONCLUSIONS: The serum NGAL levels in the IBD group was significantly higher than the HC group. Serum NGAL levels were higher in more extensive colonic involvement.
Authors: De-xiu Bu; Anne-Louise Hemdahl; Anders Gabrielsen; Jonas Fuxe; Chaoyong Zhu; Per Eriksson; Zhong-qun Yan Journal: Am J Pathol Date: 2006-12 Impact factor: 4.307
Authors: Jun Yang; David Goetz; Jau Yi Li; Wenge Wang; Kiyoshi Mori; Daria Setlik; Tonggong Du; Hediye Erdjument-Bromage; Paul Tempst; Roland Strong; Jonathan Barasch Journal: Mol Cell Date: 2002-11 Impact factor: 17.970
Authors: Davide Bolignano; Anna Della Torre; Antonio Lacquaniti; Giuseppe Costantino; Walter Fries; Michele Buemi Journal: J Investig Med Date: 2010-03 Impact factor: 2.895
Authors: Mehmet Odabasi; Atakan Yesil; Selvinaz Ozkara; Nurcan Paker; Sevil Ozkan; Cengiz Eris; Mehmet Kamil Yildiz; Hacı Hasan Abuoglu; Emre Gunay; Kemal Tekeşin Journal: Int J Clin Exp Med Date: 2014-09-15
Authors: Maureen C Turina; Nataliya Yeremenko; Floris van Gaalen; Maikel van Oosterhout; Inger J Berg; Ramona Ramonda; Cristina M C Lebre; Robert Landewé; Dominique Baeten Journal: RMD Open Date: 2017-01-11
Authors: Elena Milanesi; Maria Dobre; Teodora E Manuc; Gabriel Becheanu; Cristian G Tieranu; Elena M Ionescu; Mircea Manuc Journal: Drug Dev Res Date: 2019-07-19 Impact factor: 4.360
Authors: Jessica D Hathaway-Schrader; Nicole A Poulides; Matthew D Carson; Joy E Kirkpatrick; Amy J Warner; Brooks A Swanson; Eliza V Taylor; Michael E Chew; Sakamuri V Reddy; Bei Liu; Caroline Westwater; Chad M Novince Journal: JBMR Plus Date: 2020-01-30
Authors: Silje Thorsvik; Ingunn Bakke; Atle van Beelen Granlund; Elin Synnøve Røyset; Jan Kristian Damås; Ann Elisabet Østvik; Arne Kristian Sandvik Journal: Cell Tissue Res Date: 2018-06-05 Impact factor: 5.249